who should not take glp-1 receptor agonists Mapping the effectiveness and risks of The GLP-1 Agonists and Obesity:
Description
Accordingly, many of the neuroprotective mechanisms outlined in the discussion of DR have implications for glaucoma as well
Following tests in animals, Amylin launched trials of its new synthetic version of exendin-4 in humans
doi:10.1111/jdi.12450 59
The authors conclude: In this real-world study where half of patients discontinued GLP-1-based treatment within a year after initiation, not losing weight was associated with worse clinical outcomes while larger reductions were associated with decreased risks
However, natural GLP-1 is quickly broken down by dipeptidyl peptidase 4 (DPP4) after it is released [2]
